Role of Wnt/β-catenin signaling in drug resistance of pancreatic cancer

Current Pharmaceutical Design

Volumn 18, Issue 17, 2012, Pages 2464-2471

  Cui, Jiujie ^a   Jiang, Weihua ^a   Wang, Shuyi ^a   Wang, Liwei ^a   Xie, Keping ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Angiogenesis; Chemoresistance; Pancreatic cancer; Wnt catenin signaling

Indexed keywords

APC PROTEIN; BETA CATENIN; CAPECITABINE; CASEIN KINASE I; CASPASE; CYCLIN D1; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GELATINASE A; GEMCITABINE; GLYCOGEN SYNTHASE KINASE 3BETA; INTERLEUKIN 8; IRINOTECAN; K RAS PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; OXALIPLATIN; SONIC HEDGEHOG PROTEIN; SURVIVIN; VASCULOTROPIN; WNT PROTEIN; WNT1 PROTEIN; WNT2 PROTEIN; WNT3 PROTEIN; WNT8A PROTEIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BINDING SITE; CANCER CONTROL; CANCER PROGNOSIS; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL SURVIVAL; CENTROSOME; CHROMOSOMAL INSTABILITY; DNA DAMAGE; DOWN REGULATION; DRUG DELIVERY SYSTEM; ENZYME ACTIVATION; EPIGENETICS; G1 PHASE CELL CYCLE CHECKPOINT; GENE CONTROL; GENE MUTATION; GENE OVEREXPRESSION; HEDGEHOG; HUMAN; MOLECULAR INTERACTION; ONCOGENE C MYC; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOSENSITIZATION; S PHASE CELL CYCLE CHECKPOINT; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; UPREGULATION;

EID: 84860491093     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128112092464     Document Type: Article

References (83)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Loos M, Kleeff J, Friess H, Büchler MW. Surgical treatment of pancreatic cancer. Ann N Y Acad Sci 2008; 1138: 169-80.
3. Mimeault M, Hauke R, Batra Sk. Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther 2008; 83: 673-91.
4. Jiang L, Yuqing Z, Xianjun Y, et al. Overcoming drug resistance in pancreatic cancer. Expert Opin Ther Targets 2011; 15(7): 817-28.
5. Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 1981; 48: 1705-10.
6. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-13.
7. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-6.
8. Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009; 27: 5513-8.
9. Oberstein PE, Saif MW. First-Line Treatment for Advanced Pancreatic Cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. JOP 2011; 12: 96-100.
10. Trédan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007; 99: 1441-54.
11. Strimpakos A, Saif MW, Syrigos KN. Pancreatic cancer: from molecular pathogenesis to targeted therapy. Cancer Metastasis Rev 2008; 27: 495-522.
12. Bartsch D, Shevlin DW, Tung WS, Kisker O, Wells SA Jr, Goodfellow PJ. Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas. Genes Chromosomes Cancer 1995; 14: 189-95.
13. Dong M, Nio Y, Yamasawa K, Toga T, Yue L, Harada T. p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer. J Surg Oncol 2003; 82: 111-20.
14. Rizwan S, Naomi W, Martin C, Robert O'C, Ray M. Challenges of drug resistance in the management of pancreatic cancer. Anticancer Ther 2010; 10: 1647-61
15. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321: 1801-6.
16. Jones PM, Sam CW, Matthias H. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer 2010; 10: 683-95.
17. Bryan T. MacDonald, Keiko Tamai, Xi He. Wnt/β-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009; 17: 9-26.
18. Jennifer LF, Daya P, Samuel J. Pleasure. Wnt signaling in development and disease. Neurobiol Dis 2010; 38: 148-53.
19. Zhang J, Jia Z, Xie K, et al. Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer 2007; 109: 1478-86.
20. Michael K. The role of Wnt signaling in physiological and pathological angiogenesis. Circulation Res 2010; 107: 943-52.
21. Dilek FH, Topak N, Tokyol Ç, Akbulut G, Dilek ON. β-Catenin and its relation to VEGF and cyclin D1 expression in pT3 rectosigmoid cancers. Turk J Gastroenterol 2010; 21: 365-71.
22. Huang CL, Liu D, Ishikawa S, et al. Wnt1 overexpression promotes tumour progression in non-small cell lung cancer. Eur J Cancer 2008; 44: 2680-8.
23. Masckauchán TN, Shawber CJ, Funahashi Y, Li CM, Kitajewski J. Wnt/beta-catenin signaling induces proliferation, survival and interleukin- 8 in human endothelial cells. Angiogenesis 2005; 8: 43-51.
24. Le X, Shi Q, Wang B, et al. Molecular regulation of constitutive expression of interleukin-8 in human pancreatic adenocarcinoma. J Interferon Cytokine Res 2000; 20: 935-46.
25. Mann B, Gelos M, Siedow A, et al. Target genes of beta-catenin-T cell-factor/ lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci USA 1999; 96: 1603-8.
26. Shimokawa T, Furukawa Y, Sakai M, et al. Involvement of the FGF18 gene in colorectal carcinogenesis, as a novel downstream target of the beta-catenin/T-cell factor complex. Cancer Res 2003; 63: 6116-20.
27. Lowy AM, Clements WM, Bishop J, et al. beta-Catenin/Wnt signaling regulates expression of the membrane type 3 matrix metalloproteinase in gastric cancer. Cancer Res 2006; 66: 4734-41.
28. Brabletz T, Jung A, Dag S, Hlubek F, Kirchner T. beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol 1999; 155: 1033-8.
29. B Zhang, JX Ma. Wnt pathway antagonists and angiogenesis. Protein Cell 2010; 1: 898-906.
30. Corada M, Nyqvist D, Orsenigo F, et al. The Wnt/beta-catenin pathway modulates vascular remodeling and specification by upregulating Dll4/Notch signaling. Dev Cell 2010; 18: 938-49.
31. Muley A, Majumder S, Kolluru GK, et al. Secreted frizzled-related protein 4: an angiogenesis inhibitor. Am J Pathol 2010; 176: 1505-16.
32. Park MS, Klotz E, Kim MJ, et al. Perfusion CT: noninvasive surrogate marker for stratification of pancreatic cancer response to concurrent chemo- and radiation therapy. Radiology 2009; 250: 110-7.
33. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324: 1457-61.
34. Erkan M, Reiser-Erkan C, Michalski CW, et al. Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma. Neoplasia 2009; 11: 497-508.
35. Schwarte-Waldhoff I, Volpert OV, Bouck NP, et al. Smad4/DPC4- mediated tumor suppression through suppression of angiogenesis. Proc Natl Acad Sci USA 2000; 97: 9624-9.
36. Froeling FE, Mirza TA, Feakins RM, et al. Organotypic culture model of pancreatic cancer demonstrates that stromal cells modulate E-cadherin, beta-catenin, and Ezrin expression in tumor cells. Am J Pathol 2009; 175: 636-48.
37. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-7.
38. Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1: 313-23.
39. Immervoll H, Hoem D, Sakariassen PØ, Steffensen OJ, Molven A. Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer 2008; 8: 48.
40. Prakash N, Wurst W. A Wnt signal regulates stem cell fate and differentiation in vivo. Neurodegener Dis 2007; 4: 333-8.
41. Van de Wetering M, Sancho E, Verweij C, et al. The betacatenin/ TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002; 111: 241-50.
42. Chen MS, Woodward WA, Behbod F, et al. Wnt/beta-catenin mediates radiation resistance of Sca1+ progenitors in an immortalized mammary gland cell line. J Cell Sci 2007; 120: 468-77.
43. Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA, Rosen JM. WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci USA 2007; 104: 618-23.
44. Lu R, Bian F, Zhang X, et al. The β-catenin/Tcf4/survivin signaling maintains a less differentiated phenotype and high proliferative capacity of human corneal epithelial progenitor cells. Int J Biochem Cell Biol 2011; 43: 751-9.
45. Guo Q, Chen Y, Zhang B, Kang M, Xie Q, Wu Y. Potentiation of the effect of gemcitabine by emodin in pancreatic cancer is associated with survivin inhibition. Biochem Pharmacol 2009; 77: 1674-83.
46. Wei D, Wang L, Xie K, et al. KLF4α up-regulation promotes cell cycle progression and reduces survival time of patients with pancreatic cancer. Gastroenterology 2010; 139: 2135-45.
47. Poch B, Gansauge F, Schwarz A, et al. Epidermal growth factor induces cyclinD1 in human pancreatic carcinoma: evidence for a cyclin D1-dependent cell cycle progression. Pancreas 2001; 23: 280-7.
48. Seema G, Sabapathi S, Mansoor MA. Infulence of Cell Cycle Checkpoints and p53 Function on the Toxicity of Temozolomide in Human Pancreatic Cancer Cells. Pancreatology 2010; 10: 565-79.
49. Sanjit KR, Rakesh KS, Sharmila S. Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. J Mol Signal 2010; 5: 1-13.
50. Garcea G, Neal CP, Pattenden CJ, Steward WP, Berry DP. Molecular prognostic markers in pancreatic cancer: a systematic review. Eur J Cancer 2005; 41: 2213-36.
51. Qiao Q, Ramadani M, Gansauge S, Gansauge F, Leder G, Beger HG. Reduced membranous and ectopic cytoplasmic expression of beta -catenin correlate with cyclin D1 overexpression and poor prognosis in pancreatic cancer. Int J Oncol 2002; 21: 37-42.
52. Kornmann M, Danenberg KD, Arber N, Beger HG, Danenberg PV, Korc M. Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes. Cancer Res 1999; 59: 3505-11.
53. Qi Y, Tu Y, Yang D, et al. Cyclin A but not cyclin D1 is essential for c-myc-modulated cell-cycle progression. J Cell Physiol 2007; 210: 63-71.
54. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclindependent kinases. Cell 1993; 75: 805-16.
55. Lee MH, Reynisdóttir I, Massagué J. Cloning of p57KIP2, a cyclindependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 1995; 9: 639-49.
56. Polyak K, Kato JY, Solomon MJ, et al. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 1994; 8: 9-22.
57. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701-4.
58. Schild C, Wirth M, Reichert M, Schmid RM, Saur D, Schneider G. PI3K signaling maintains c-myc expression to regulate transcription of E2F1 in pancreatic cancer cells. Mol Carcinog 2009; 48: 1149-58.
59. Reichert M, Saur D, Hamacher R, Schmid RM, Schneider G. Phosphoinositide- 3-kinase signaling controls S-phase kinase-associated protein 2 transcription via E2F1 in pancreatic ductal adenocarcinoma cells. Cancer Res 2007; 67: 4149-56.
60. Orford K, Orford CC, Byers SW. Exogenous expression of betacatenin regulates contact inhibition, anchorage-independent growth, anoikis, and radiation-induced cell cycle arrest. J Cell Biol 1999; 146: 855-68.
61. Bahmanyar S, Kaplan DD, Deluca JG, et al. beta-catenin is a Nek2 substrate involved in centrosome separation. Genes Dev 2008; 22: 91-105.
62. Fumoto K, Kadono M, Izumi N, Kikuchi A. Axin localizes to the centrosome and is involved in microtubule nucleation. EMBO Rep 2009; 10: 606-13.
63. Caldwell CM, Kaplan KB. The role of APC in mitosis and in chromosome instability. Adv Exp Med Biol 2009; 656: 51-64.
64. Kockeritz L, Doble B, Patel S, Woodgett JR. Glycogen synthase kinase-3--an overview of an over-achieving protein kinase. Curr Drug Targets 2006; 7: 1377-88.
65. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002; 2: 277-88.
66. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapyinduced apoptosis in a human leukemia cell line. Blood 1993; 81: 151-7.
67. Arlt A, Müerköster SS, Schäfer H. Targeting apoptosis pathways in pancreatic cancer. Cancer Lett 2010; 13: [Epub ahead of print].
68. Almendro V, Ametller E, García-Recio S, et al. The role of MMP7 and its cross-talk with the FAS/FASL system during the acquisition of chemoresistance to oxaliplatin. PLoS One 2009; 4: e4728.
69. Ristorcelli E, Beraud E, Verrando P, et al. Human tumor nanoparticles induce apoptosis of pancreatic cancer cells. FASEB J 2008; 22: 3358-69.
70. Chada S, Bocangel D, Ramesh R, Grimm EA, Mumm JB, Mhashilkar AM, et al.mda-7/IL24 kills pancreatic cancer cells by inhibition of the Wnt/PI3K signaling pathways: identification of IL-20 receptor-mediated bystander activity against pancreatic cancer. Mol Ther 2005; 11: 724-33.
71. Steigerwald K, Behbehani GK, Combs KA, Barton MC, Groden J. The APC tumor suppressor promotes transcription-independent apoptosis in vitro. Mol Cancer Res 2005; 3: 78-89.
72. Li F, Chong ZZ, Maiese K. Winding through the WNT pathway during cellular development and demise. Histol Histopathol 2006; 21: 103-24.
73. Pasca di Magliano M, Biankin AV, Heiser PW, et al. Common activation of canonical Wnt signaling in pancreatic adenocarcinoma. PLoS One 2007; 2: e1155.
74. Chen S, Guttridge DC, You Z, et al. Wnt-1 signaling inhibits apoptosis by activating beta-catenin/T cell factor-mediated transcription. J Cell Biol 2001; 152: 87-96.
75. Shah AN, Summy JM, Zhang J, Park SI, Parikh NU, Gallick GE. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol 2007; 14: 3629-37.
76. Singh S, Srivastava SK, Bhardwaj A, Owen LB, Singh AP. CXCL12-CXCR4 signaling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy. Br J Cancer 2010; 103: 1671-9.
77. Saifo MS, Rempinski DR Jr, Rustum YM, Azrak RG. Targeting the oncogenic protein beta-catenin to enhance chemotherapy outcome against solid human cancers. Mol Cancer 2010; 9: 310-21.
78. Deng R, Tang J, Ma JG, et al. PKB/Akt promotes DSB repair in cancer cells through upregulating Mre11 expression following ionizing radiation. Oncogene 2011; 30: 944-55.
79. Ewald B, Sampath D, Plunkett W. ATM and the Mre11-Rad50- Nbs1 complex respond to nucleoside analogue-induced stalled replication forks and contribute to drug resistance. Cancer Res 2008; 68: 7947-55.
80. Yamada T, Takaoka AS, Naishiro Y, et al. Transactivation of the multidrug resistance 1 gene by T-cell factor 4/beta-catenin complex in early colorectal carcinogenesis. Cancer Res 2000; 60: 4761-6.
81. Dieudonné FX, Marion A, Haÿ E, Marie PJ, Modrowski D. High Wnt signaling represses the proapoptotic proteoglycan syndecan-2 in osteosarcoma cells. Cancer Res 2010; 70: 5399-408.
82. O'Driscoll L, Walsh N, Larkin A, et al. MDR1/P-glycoprotein and MRP-1 drug efflux pumps in pancreatic carcinoma. Anticancer Res 2007; 27: 2115-20.
83. Hrabar D, Aralica G, Gomercic M, Ljubicic N, Kruslin B, Tomas D. Epithelial and stromal expression of syndecan-2 in pancreatic carcinoma. Anticancer Res 2010; 30: 2749-53.